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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To compare the available dressings and securement devices for CVCs, in terms of catheter-related bloodstream infection (CR-BSI),
catheter colonisation, entry and exit site infection, skin colonisation, skin irritation, accidental catheter removal (complete or partial),
dressing condition and mortality.
B A C K G R O U N D
Description of the condition
Central venous catheters (CVCs) play an important role in the
management of patients, serving as reliable vascular access and the
site of venous pressure monitoring. They are inserted when a pa-
tient requires venous access over an extended period of time, and
allow the intravenous administration of complex drug treatments,
blood products and nutritional support without the trauma asso-
ciated with repeated needle insertions (Webster 2011). Although
mostly used in intensive-care units and oncology settings, CVCs
are increasingly being used in other wards and outpatient settings.
There are multiple types of CVCs in use throughout clinical prac-
tice. A CVC can be designated by: its intended life span (e.g. tem-
porary or short-term versus permanent or long-term); its site of
insertion (e.g. subclavian, femoral, internal jugular or peripherally
inserted central catheter (PICC)); its pathway from skin to vessel
(e.g. tunnelled versus nominee); its physical length (e.g. long ver-
sus short) or some other special characteristic(s) (e.g. impregnation
with heparin or number of lumens) (O’Grady 2011). More infor-
mation regarding the variety of catheters used in clinical practice
is included in Appendix 1.
Owing to the invasive procedure necessary for placing a CVC and
the resulting break in the skin (integument), complications such as
exit-site infections and bloodstream infections can develop (Han
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2010). A serious complication of CVCs is catheter-related blood
stream infections (CR-BSI), also known as ’catheter sepsis’. CR-
BSI rates are influenced by patient-related factors, such as sever-
ity and type of illness (e.g. full-thickness burns versus post-car-
diac surgery), by catheter-related factors (such as the condition
under which the catheter was placed and catheter type), and by
institutional factors (e.g. bed size, academic affiliation) (O’Grady
2011).Many studies have estimated the incidence of CR-BSI, gen-
erally reporting a range between 1 and 3.1 per 1000 patient days
(Pronovost 2006; Schwebel 2012), but rates have been shown to
decrease to zero after interventions (Han 2010). The attributable
cost of CR-BSI varies between USD 3124 and USD60,536 per
event (Raad 2007; Schwebel 2012), and is associated with an at-
tributable mortality of 0% to 11.5% (Timsit 2011).
CVCs are foreign objects, and, as such, require their external com-
ponent both to be protected adequately from microbial contami-
nation from the surrounding environment and secured to the skin.
Dressings and securements must ensure CVCs do not dislodge or
fall out (or both), or move within or out of the great veins. This
can occur via movement or pressure on the external component of
the device, through forced removal, or ‘drag’ from infusion tubing
or ‘catching’ on environmental structures (Naimer 2004). Move-
ment of the CVC to a location outside the target placement can
result in line failure or cardiovascular instability. In critical situa-
tions line failure (e.g. the interruption of inotropic support dur-
ing cardiogenic shock) can have catastrophic consequences for the
patient’s morbidity and mortality.
Description of the intervention
There is a plethora of CVC dressings and securements fromwhich
clinicians may select. The earliest securement approach was simple
tape or gauze-tape, with plastic filmdressings becomingprominent
in the 1980s. First-generation occlusive standard polyurethane
(SPU)dressings were later developed to become semi-permeable to
oxygen, carbon dioxide and water vapour (e.g. OpSite IV 3000®,
Smith and Nephew; Tegaderm Plus®, 3M), as occlusive dress-
ings trap moisture on the skin and provide an ideal environment
for quick growth of local microflora (Frasca 2010). Each dress-
ing is transparent, permitting continuous visual inspection of the
catheter site. A recent approach toCVCsecurement is the bordered
polyurethane (BPU) dressing that retains the central polyurethane
component of SPU dressings with an added external adhesive bor-
der of foam or cloth fabric tomaximise catheter security (e.g. Tega-
derm Advanced®, 3M).
The majority of CR-BSI are caused by micro-organisms found
in the patient’s own commensal skin flora, such as Staphylococ-
cus epidermidis and Staphylococcus aureus (Timsit 2011); conse-
quently, we have seen the arrival of medication-impregnated dress-
ings in recent years. The most common of these are the chlorhex-
idine gluconate-impregnated (CGI) dressings. These CGI dress-
ings release chlorhexidine-gluconate on the cutaneous underly-
ing surface when placed over the catheter insertion site (Arvaniti
2012). Chlorhexidine gluconate is a cationic biquanide that pro-
vides rapid antisepsis because of its broad spectrum of germicidal
activity against most CR-BSI-causing pathogens (Garland 2001).
The chlorhexidine gluconate impregnates the whole dressing, or
is applied using an impregnated sponge (e.g. Biopatch®) and cov-
ered by a transparent polyurethane dressing. Other medication-
impregnated dressings discussed in the literature include silver-
impregnated and iodine-impregnated dressings (Wille 1989). The
iodine-impregnated dressings release free iodine when exposed to
wound exudate, while the silver-impregnated dressings expose the
entrance site to silver ions, which are thought to have antimicro-
bial properties. Some researchers recommend the use of hydrocol-
loidal dressings for the dressing of CVCs. This type is tradition-
ally used on open wound sites to promote moist healing as, as the
hydrocolloid matrix absorbs excess moisture away from the skin
surface, it reduces the likelihood of microbial growth (Nikoletti
1999).
Securement of the CVC is also facilitated by mechanisms other
than dressings. Traditionally, CVCs were routinely sutured in
place, prior to a dressing being applied (O’Grady 2011). In ad-
dition to this option, clinicians frequently reinforced the device
security using non-commercial options including sterile strips or
non-sterile tape. Recently, sutureless securement devices (SSD)
have become available commercially. These are used in addition
to transparent dressings, and use a large adhesive footplate and
an underlying pad with an device-locking clasp (e.g. Statlock®,
Bard). These, theoretically, reduce movement, kinking and flow
impedance, maximising catheter stabilisation (Yamamoto 2002).
Each of these CVC dressing and securement types has different
therapeutic goals and is readily available for clinicians and patients
to purchase from numerous suppliers. The diversity of dressings
and securements available to clinicians (including variation within
each of the types discussed above) makes evidence-based decision-
making difficult in this area. With the availability of increasingly
sophisticated and expensive CVCdressings and securements, prac-
titioners need to know how effective these dressings are compared
with more traditional dressings.
How the intervention might work
The ideal CVC dressing should:
1. provide a barrier protection from colonisation and
infection, preventing CR-BSI;
2. provide adequate securement to prevent accidental removal,
partial dislodgement and micro-motion, preventing CVC failure;
3. be comfortable and non-irritating for the patient;
4. be easy to use; and
5. be cost-effective.
Several studies have reported the effectiveness of interventions to
reduce CR-BSI rates, including maximal sterile precautions dur-
ing insertion, skin antisepsis, securement devices and antimicro-
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bial coatings (Levy 2005; Han 2010; Timsit 2011). The role of
the CVC dressing in preventing CR-BSI is to provide a barrier
protection, thereby preventing migration of skin organisms at the
insertion site into the cutaneous catheter tract - and subsequent
colonisation of the catheter tip - and preventing direct contami-
nation of the catheter by contact with hands and other materials
(O’Grady 2011).
Why it is important to do this review
Decreasing the incidence of CR-BSI and preventing CVC fail-
ure are important objectives with a significant impact on patient
morbidity and mortality, yet there is no consensus on the optimal
dressing type to use with CVCs, despite more than two decades of
research and debate. The recent Cochrane review “Gauze and tape
and polyurethane dressings for CVC” focused on only two product
types (Webster 2011), and, therefore, does not adequately address
the variety of products now available in the clinical environment.
A large variety of dressings and types of securement are currently
available for use with CVCs, as well as reports frommany research
studies that used different outcomes and comparisons.
O B J E C T I V E S
To compare the available dressings and securement devices for
CVCs, in terms of catheter-related bloodstream infection (CR-
BSI), catheter colonisation, entry and exit site infection, skin
colonisation, skin irritation, accidental catheter removal (complete
or partial), dressing condition and mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) that have evaluated the
effects of CVC dressings and securements for their impact on
CR-BSI, catheter colonisation, entry and exit site infection, skin
colonisation, skin irritation, catheter security, dressing condition
or mortality, irrespective of publication status or language. We will
include controlled clinical trials (CCTs) only in the absence of
RCTs. CCTs refer to quasi-randomised studies where, although
the trial involves testing an intervention and control, with concur-
rent enrolment and follow-up of test and control-treated groups,
the method of allocation is not considered to be strictly random
(Lefebvre 2011). Cross-over and cluster-randomised trials will not
be included.
Types of participants
Any participant requiring a CVC in any healthcare or community
setting. Age will not be an excluding factor. All CVCs will be
included, i.e. short- and long-term CVCs, tunnelled and non-
tunnelled, port-a-caths, haemodialysis catheters, and peripherally-
inserted central catheters (PICCs).
Types of interventions
Trials comparing any CVC dressings or securements including
(but not limited to):
Dressings
• Gauze and tape.
• Standard polyurethane (SPU) dressings.
• Bordered polyurethane (BPU) dressings.
• Chlorhexidine gluconate-impregnated (CGI) dressings.




• Sutureless securement devices (SSD).
Types of outcome measures
Primary outcomes
• Incidence of catheter-related blood stream infection (BSI):
as defined by one of the following three criteria:
i) Primary bacteraemia/fungaemia with at least one
positive blood culture from a peripheral vein with no other
identifiable source for the BSI other than the intravascular device
(IVD), plus, one of: a positive semiquantitative (> 15 colony-
forming units (cfu)) or quantitative (> 103 cfu) device culture,
with the same organism (species and antibiogram) isolated from
the device and blood (O’Grady 2002; Maki 2006).
ii) Two blood cultures (one from an IVD hub and one
from a peripheral vein), that both meet the CR-BSI criteria for
quantitative blood cultures (three-fold greater colony count of
growth for the same organism as from the peripheral blood), or
differential time to positivity (DTP) (growth of the same
microbe from hub drawn blood at least two hours before growth
from the peripheral blood).
iii) Two quantitative blood cultures of samples obtained
through two catheter lumens in which the colony count for the
blood sample drawn through one lumen is at least three-fold
greater than the colony count for the blood sample from the
second lumen (Mermel 2009).
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Secondary outcomes
• Frequency of CR-BSI per 1000 patient days: CR-BSI as
previously defined.
• Incidence of catheter tip colonisation: positive semi-
quantitative (> 15 cfu/catheter segment) or quantitative (> 103
cfu/catheter segment) culture from a proximal or distal catheter
segment (O’Grady 2002).
• Incidence of entry and exit site infection: as described by
the trial investigator.
• Incidence of skin/site colonisation: positive semi-
quantitative (> 15 cfu) or quantitative (>103 cfu) culture from
the skin around the catheter site (O’Grady 2002).
• Incidence of skin irritation or damage: as described by the
study investigator using a formal assessment tool.
• Incidence of failed catheter securement: frequency of
accidental or forced removal or dislocation resulting in CVC
failure.
• Dressing condition/durability: incidence or mean score
using a formal assessment tool.
• Mortality from any cause.
We will construct a summary of findings table using Grade-
PRO to display the main overall results of the primary outcome
(Schunemann 2011), including relative effects and quality of the
evidence.
Search methods for identification of studies
Electronic searches
Wewill search the following electronic databases to identify reports
of relevant randomised clinical trials:
• The Cochrane Wounds Group Specialised Register;
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library) (Latest issue);
• Ovid MEDLINE (1946 to present);
• Ovid EMBASE (1974 to present);
• EBSCO CINAHL (1982 to present)
We will use the following provisional search strategy in The
Cochrane Central Register of Controlled Trials (CENTRAL):
#1MeSH descriptor: [Catheterization, Central Venous] explode
all trees
#2(venous near/3 (catheter* or line*)):ti,ab,kw




#7MeSH descriptor: [Catheters, Indwelling] explode all trees
#8(“implantable vascular access device” or IAVD or PortACath):
ti,ab,kw
#9(“peripherally inserted central catheter” or PICC):ti,ab,kw
#10(h*emodialysis next catheter*):ti,ab,kw
#11#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12MeSH descriptor: [Occlusive Dressings] explode all trees
#13MeSH descriptor: [Bandages, Hydrocolloid] explode all trees
#14MeSH descriptor: [Silver] explode all trees
#15MeSH descriptor: [Silver Sulfadiazine] explode all trees
#16MeSH descriptor: [Polyurethanes] explode all trees
#17MeSH descriptor: [Iodine] explode all trees
#18MeSH descriptor: [Chlorhexidine] explode all trees
#19((occlusive* or hydrocolloid* or silver* or polyurethane* or
permeable or nonpermeable or non-permeable or transparent or
chlorhexidine or iodine* or gauze or tape) near/3 (dressing* or
sponge*)):ti,ab,kw
#20#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19
#21#11 and #20
We will adapt this strategy to search Ovid MEDLINE, Ovid EM-
BASE and EBSCO CINAHL. We will combine the Ovid MED-
LINE search with the Cochrane Highly Sensitive Search Strategy
for identifying randomised trials in MEDLINE: sensitivity- and
precision-maximising version (2008 revision) (Lefebvre 2011).We
will combine the EMBASE search with the Ovid EMBASE filter
developed by the UK Cochrane Centre (Lefebvre 2011). We will
combine the CINAHL searches with the trial filters developed by
the Scottish IntercollegiateGuidelinesNetwork (SIGN 2012).We
will not restrict studies with respect to language, date of publica-
tion or study setting.
We will also search the following clinical trial registers:
• Clinical Trial www.clinicaltrial.gov;
• Current Controlled Trials www.controlled-trials.com/mrct;
• Hong Kong clinical trials register www.hkclinicaltrials.com;
• Indian clinical trials registry www.ctri.in;
• UK Clinical Trials Gateway www.controlled-trials.com/
ukctr/ and,
• the World Health Organization (WHO) search portal
www.who.int/trialsearch.
Searching other resources
We will handsearch bibliographies of all retrieved and relevant
publications identified by these strategies for further relevant stud-
ies. We will contact experts in the field to ask for information rel-
evant to this review. We will also contact dressing and securement
devicemanufacturers, including companies such as 3M, andSmith
and Nephew, for possible unpublished data in order to counteract
publication bias.
Data collection and analysis
Selection of studies
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Independently, two review authors (AU andMM) will assess titles
and abstracts of retrieved studies for relevance. After this initial
assessment, full versions of all potentially eligible studies will be
retrieved. Independently, the same two review authors will then
check the full papers for eligibility. Discrepancies between review-
ers will be resolved through discussion and, where required, a third
independent review author (CR) will be consulted. A list of all
studies, including excluded studies and reasons for their exclusion
will be published for transparency using the PRISMA flowchart
(Liberati 2009).
Data extraction and management
Details from eligible studies will be extracted and summarised us-
ing a data extraction sheet. Due to the large number of studies it
is predicted will be included in this review, teams of two review
authors will review specific interventions including: CGI dressing
studies, gauze studies, SSD studies, paediatric and neonatal stud-
ies, and remaining studies. These teams will extract data indepen-
dently and then cross check them for accuracy and agreement.
Any discrepancies will be resolved though discussion and arbitra-
tion by a third review author, if necessary. For studies that have
been published in duplicate, we will extract maximal data from all
relevant publications, but we will not duplicate data in analyses. If
there are any data missing from the papers, then attempts will be
made to contact the authors to retrieve the missing information.
A data extraction sheet will be used to extract summary data from
each trial. The data extraction sheet will contain baseline charac-
teristics of the study, including control group participants: their
number; age; gender; disease; treatment; type of CVC; number of
catheter lumens; time in situ (dwell time) of the CVC, dressing
and/or securement; number of dressing changes during the dwell
time of the CVC; known allergies to dressings; skin complexion;
known history of, or current, positive blood cultures; and health-
care setting in which the intervention occurred. We will list each
trial’s criteria for patient inclusion and exclusion, a description of
the intervention(s), the number of patients randomised to each
intervention and primary and secondary outcome measures.
Assessment of risk of bias in included studies
Each eligible study will be independently assessed for quality and
bias using the Cochrane Collaboration ‘Risk of bias assessment
tool’. This tool addresses six specific domains, namely, sequence
generation, allocation and concealment, blinding, incomplete out-
come data, selective outcome reporting, and other issues that po-
tentially may bias the study (Higgins 2011a). A ‘Risk of bias’ table
will be completed for each eligible study. A separate assessment of
blinding and completeness of outcome data will be conducted for
each outcome. Discrepancies between reviewers will be resolved
through discussion. Findings will be presented using the ‘Risk of
bias’ summary figure that will present all judgements in a cross-
tabulation of study by entry.
Measures of treatment effect
Our primary analysis will involve pair-wise comparisons of treat-
ment effect between dressing and securement types, using all the
described outcomes. For dichotomous outcomes, we will calculate
risk ratio (RR) plus 95% confidence intervals (CI). For continu-
ous outcomes, we will calculate mean difference (MD) plus 95%
CIs. For outcomes best presented as a rate per time period, we
will use hazard ratios (HR) and standard errors (SE) to inform
inverse-variance analysis. In addition, some of our secondary out-
comes may be measured using ordinal scales. For simplicity, we
will assume that these are continuous, and analyse data with the
standardised mean difference (SMD). It is also possible that dif-
ferent tools may be used to measure the same outcome (e.g. skin
damage). We will collect data only from those studies that used a
formalised assessment tool. We will use the SMD as the summary
statistic in any meta-analysis of such data.
In addition to the main pair-wise analysis described above, in
order to inform clinical decision-making we will undertake pair-
wise comparisons using the ’clustering’ of interventions on the
basis of patient treatment goals and outcomes. This will involve
comparison of:
CR-BSI
• Medication-impregnated dressings (CGI, povidone-iodine
and silver-impregnated) versus non-impregnated dressings (SPU,
BPU, gauze and tape, hydrocolloidal).
• CGI-impregnated dressings versus all other medication-
impregnated dressings (povidone-iodine, silver).
• Silver-impregnated dressings versus all other medication-
impregnated dressings (povidone-iodine, CGI).
• Povidine-iodine impregnated dressings versus all other
medication-impregnated dressings.
• Gauze and tape versus SPU and BPU.
Incidence of skin irritation or damage
• Hydrocolloidal dressing versus all other.
• Gauze and tape versus SPU and BPU.
• CGI-impregnated versus SPU and BPU.
Failed catheter securement
• BPU versus all non-bordered dressings (SPU,
hydrocolloidal).
• SSD versus all other dressing types.
• No dressing versus all other dressing types.
These clustering comparisons will be done because of the hetero-
geneity of populations that use CVCs, and the way their goals
for treatment differ. In order to minimise bias, these clustering
5Dressings and securement devices for central venous catheters (CVC) (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
comparisons have been identified prior to undertaking the anal-
yses. Additionally, at the conclusion of the review we will con-
sider undertaking a ’multiple-treatments meta-analysis’ in order to
summarise the results further, and so to assist clinicians in making
meaningful-decisions (Salanti 2008; Higgins 2011b).
Unit of analysis issues
We do not anticipate any unit of analysis issues. It is expected that
the RCTs/CCTs will randomise participants and not their CVCs.
For studies where CVCs are randomised, rather than participants,
we will only include the first CVC per participant. Cross-over and
cluster-randomised trials will not be included.
Dealing with missing data
If there is evidence of missing data, attempts will be made to
contact the study authors to request the missing information. If,
after several attempts to contact the author, the missing data have
not been provided, we will analyse the available data only. We
will also address the potential impact of the missing data on the
findings of the review in the discussion.
Assessment of heterogeneity
We will consider clinical, methodological and statistical hetero-
geneity and will undertake an assessment of comparability of the
studies prior to meta-analysis. We will investigate the degree of
statistical of heterogeneity, that is, variation between the true inter-
vention effects underlying the different studies, by a combination
of methods. This will involve visual inspection of the meta-ana-
lytic model and interpretation of the Chi2 and I2 statistics that ex-
amine the total variance across studies due to heterogeneity rather
than chance (Higgins 2003). If significant levels of heterogeneity
are identified using these criteria, we will explore the heterogene-
ity through subgroup analyses and a sensitivity analysis (with and
without the exclusion of outlying studies), and, if a Chi2 P value
of less than 0.10 remains, and an I2 of greater than 50% (Higgins
2011a), we will consider not undertaking a meta-analysis.
Assessment of reporting biases
We will report each outcome separately. We will use funnel plots
to assess reporting biases, if sufficient studies are included in the
review. We will undertake an observation of small-study effects if
required.
Data synthesis
Initially we will conduct a structured narrative summary of the
studies included in the review. We will enter quantitative data into
RevMan 5.1and analyse them using RevMan analysis software. If
appropriate, data will be pooled for meta-analysis using RevMan
5.1. We will use a random-effects model because of the predicted
clinical heterogeneity.
Subgroup analysis and investigation of heterogeneity
If sufficient data are available we will undertake the following
subgroup analysis for the primary outcomes:
• Adult participants versus paediatric participants versus
neonatal participants.
• Participants diagnosed with haematology/oncology
conditions versus other participants.
• CVC type (tunnelled versus non-tunnelled, short-term
versus long-term, dialysis versus non-dialysis, PICC versus
centrally-inserted CVC).
• Participants receiving the intervention in an acute versus a
community setting.
• Participants receiving lipid and parenteral nutrition (PN)
versus patients not receiving lipid and PN.
Sensitivity analysis
We will perform a sensitivity analysis by excluding studies as indi-
cated by the results of the final meta-analysis. This will probably
involve the exclusion of the studies of the lowest quality. In this
sensitivity analysis, we will only include studies that are assessed as
having a low risk of bias in all key domains, namely adequate gen-
eration of the randomisation sequence, adequate allocation con-
cealment, and blinding of outcome assessor, for the estimates of
treatment effect.
A C K N OW L E D G E M E N T S
The authors would like to thank Sally Bell-Syer, (Managing Ed-
itor, Cochrane Wounds Review Group) and Ruth Foxlee (Trial
Search Co-ordinator, Cochrane Wounds Review Group) for their
assistance in preparation of this protocol.The authors would like
to acknowledge the contribution of the peer referees: Giovanni
Casazza, Debra Fayter, Tom Potokar, Dirk Ubbink, NicolaWaters
and copy editor Elizabeth Royle.
TheNHMRChas provided funding for this review from its Centre
of Research Excellence Scheme, which funds one or more of the
authors.
6Dressings and securement devices for central venous catheters (CVC) (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Arvaniti 2012
Arvaniti K, Lathyris D, Clouva-Molyvdas P, Haidich AB,
Mouloudi E, Synnefaki E, et al. Comparison of oligon
catheters and chlorhexidine impregnated sponges with
standard multilumen central venous catheters for prevention
of associated colonization and infections in intensive care
unit patients: a multicenter, randomized, controlled trial.
Critical Care Medicine 2012;40(2):420–9.
Frasca 2010
Frasca D, Dahyot-Fizelier C, Mimoz O. Prevention of
central venous catheter-related infection in the intensive
care unit. Critical Care 2010;14:212.
Garland 2001
Garland J, Alex C, Mueller C, Otten D, Shivpuri C, Harris
M, et al. A randomized trial comparing povidone-iodine
to a chlorhexidine gluconate-impregnated dressing for
prevention of central venous catheter infections in neonates.
Pediatrics 2001;107(6):1431–7.
Han 2010
Han Z, Liang S, Marschall J. Current strategies for the
prevention and management of central line-associated
bloodstream infections. Infection and Drug Resistance 2010;
10(3):147–63.
Higgins 2003
Higgins J, Thompson S, Deeks J, Altman D. Measuring
inconsistency in meta-analyses. BMJ 2003;327(7414):
557–60.
Higgins 2011a
Higgins JPT, Altman DG, Stern JAC on behalf of the
Cochrane Statistical Methods Group and the Cochrane
Bias Methods Group. Chapter 8: Assessing risk of
bias in included studies. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Higgins 2011b
Higgins JPT, Deeks JJ, Altman DG (editors). Chapter
16: Special topics in statistics. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville F. Chapter 6: Searching
for studies. In: Higgins JPT, Green S (editors). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Levy 2005
Levy I, Katz J, Solter E, Samra Z, Vidne B, Birk E, et
al. Chlorhexidine-impregnated dressing for prevention
of colonization of central venous catheters in infants and
children. Pediatric Infectious Disease Journal 2005;24(8):
676–9.
Liberati 2009
Liberati A, Alteman DG, Tetzlaff J, Murow C, Gotzsche
PC, Ionnidis JP, et al. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration.
PLoS Medicine 2009;6:e100001000.
Maki 2006
Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream
infection in adults with different intravascular devices: a
systematic review of 200 published prospective studies.
Mayo Clinic Proceedings 2006;81(9):1159–71.
Mermel 2009
Mermel LA, Allon M, Bouza E, Craven DE, Flynn P,
O’Grady N, et al. Clinical practice guidelines for the
diagnosis and management of intravascular catheter-related
infection: 2009 update by the Infectious Diseases Society of
America. Clinical Infectious Diseases 2009;49:1–45.
Naimer 2004
Naimer S, Temira F. Evaluation of techniques for
intravenous catheter and tubing fixation. Military Medicine
2004;169(1):79–81.
Nikoletti 1999
Nikoletti S, Leslie G, Gandossi S, Coombs G, Wilson R.
A prospective, randomized, controlled trial comparing
transparent polyurethane and hydrocolloid dressings for
central venous catheters. American Journal of Infection
Control 1999;27(6):488–96.
O’Grady 2002
O’Grady NP, Alexander M, Dellinger EP, Gerberding JL,
Heard SO, Maki DG, et al. Guidelines for the prevention
of intravascular catheter-related infections. Morbidity and
Mortality Weekly Report 2002;51(RR-10):1–29.
O’Grady 2011
O’Grady N, Alexander M, Burns L, Dellinger E, Garland J,
Heard S, et al. Guidelines for the prevention of intravascular
catheter-related infections. Clinical Journal of Infectious
Diseases 2011 May;52(9):1087–99.
Pronovost 2006
Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu
H, Cosgrove S, et al. An intervention to decrease catheter-
related bloodstream infections in the ICU. New England
Journal of Medicine 2006;355(26):2725–32.
Raad 2007
Raad I, Hanna H, Maki D. Intravascular catheter-
related infections: advances in diagnosis, prevention, and
management.. Lancet 2007;7:645–57.
Salanti 2008
Salanti G, Higgins J, Ades AE, Ioannidis JP. Evaluation of
networks of randomized trials. Statistical Methods in Medical
Research 2008;17(3):279–301.
7Dressings and securement devices for central venous catheters (CVC) (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schunemann 2011
Schunemann JH, Oxman AD, Higgins JPF, Vist GE,
Glasziou P, Guyatt GH. Chapter 11: Presenting results
and ’Summary of findings’ tables. In: Higgins JPT,
Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 [updated March
2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Schwebel 2012
Schwebel C, Lucet JC, Vesin A, Arrault X, Valcino-
Gunther S, Bouadma L, et al. Economic evaluation of
chlorhexidine-impregnated sponges for preventing catheter-
related infections in critically ill adults in the Dressing
Study. Critical Care Medicine 2012;40(1):11–7.
SIGN 2012
Scottish Intercollegiate Guidelines Network (SIGN). Search
filters. http://www.sign.ac.uk/methodology/filters.html#
random (accessed 19 November 2012).
Timsit 2011
Timsit JF, Duboid Y, Minet C, Bonadona A, Lugosi M,
Ara-Somohano C, et al. New materials and devices for
preventing catheter-related infections. Annals of Intensive
Care 2011;1:34. [DOI: 10.1186/2110-5820-1-34.]
Webster 2011
Webster J, Gillies D, O’Riordan E, Sherriff KL, Rickard
CM. Gauze and tape and transparent polyurethane
dressings for central venous catheters. Cochrane Database
of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/
14651858.CD003827.pub2]
Wille 1989
Wille J, Blusse van Oud Albas A. A comparison of four
film-type dressings by their anti-microbial effect on the flora
of the skin. Journal of Hospital Infection 1989;14(2):153–8.
Yamamoto 2002
Yamamoto A, Solomon J, Soulen M, Tang J, Parkinson
K, Lin R, et al. Sutureless securement device reduces
complications of peripherally inserted central venous
catheters. Journal of Vascular and Interventional Radiology
2002;13:77–81.
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. Types of central venous catheters (CVCs) used
Catheter type Entry site Length
Non-tunnelled central venous catheters Percutaneously inserted into central veins
(subclavian, internal jugular or femoral)
≥ 8 cm depending on patient size
Peripherally inserted central venous
catheters (PICC)
Inserted into basilic, cephalic or brachial
veins and enter the superior vena cava
≥ 20 cm depending on patient size
Tunneled central venous catheters Implanted into subclavian, internal jugular,
or femoral veins
≥ 8 cm depending on patient size
Totally implantable Tunnelled beneath skin and have subcu-
taneous port accessed with a needle; im-
planted in subclavian or internal jugular
vein
≥ 8 cm depending on patient size
O’Grady 2011 p 22
≥ = greater than or equal to
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